MEDFORD, Mass., July 14, 2016 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a reproductive medical device company that was granted FDA clearance for the first in vivo, vaginal incubation system, the INVOcell™, today announced the first partnership to offer the INVO Procedure in the state of California with the Alta Bates IVF Program in Berkeley and Marin Fertility Center in Greenbrae.
Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory petri dish, the INVOcell utilizes the women's body as a natural incubator making it an in vivo procedure. "A Simpler Way to Life," the patented INVO™ fertility treatment solution is a streamlined, lower cost procedure compared to traditional IVF. The INVO Procedure uses mild stimulation that reduces the risks to the woman and simplifies patient care while reducing the overall costs to the patient and physician. The INVO fertility treatment procedure may produce live birth rates similar to traditional IVF while adding the benefits of a more natural, simpler and lower cost treatment.
The Alta Bates IVF Program in Berkeley, CA was founded in 1984 by Dr. Richard Chetkowski. Dr. Christopher Herndon, who joined the program in 2011, has been an early leader in the movement to expand access to infertility care in the United States:
Dr. Christopher Herndon of the Alta Bates IVF Program in Berkeley, commented, "In discussions of fertility care, the staggering disparities in access to care due to the cost of IVF have long been the elephant in the room. The high costs of treatment only add to what is already a stressful experience and for far too many can be prohibitive. INVOcell is an elegantly simple solution that has the potential to be a game changer. We are proud to be among the first to offer this service to our patients."
The Marin Fertility Center was founded by Dr. Peter Uzelac. Dr. Uzelac is known to be an early adopter of new techniques enabling him to offer additional treatments and advanced care to his patients.
"We couldn't be more pleased with our ability to now offer INVOcell. This system is the perfect addition to our line of simpler, more natural, patient-friendly infertility treatments," commented Dr. Uzelac.
"INVO Bioscience is thrilled that these partnering clinics will be the first fertility clinics in the state of California to offer the novel INVOcell and INVO Procedure," stated Shelley Hossenlopp, VP of Sales and Marketing at INVO Bioscience. "With California being one of the largest and most populous areas in the country, we feel this launch will jumpstart our mission to expand care and access to fertility treatment across the U.S. By offering patients a less expensive treatment option with the advantage of equivalent pregnancy rates to traditional IVF, fertility care to patients including those previously underserved will be expanded. This is a very promising new technology and treatment option for the approximate 15% of the population that are facing infertility. INVO Bioscience continues its journey to rapidly expand care and access to more affordable fertility treatment options through additional partnerships with physicians across the U.S."
About the Alta Bates IVF Program, Berkeley, CA
Alta Bates IVF Program, a fertility clinic established in 1984 by Richard Chetkowski, MD in Berkeley, CA, provides the full range of infertility services, including IVF, ICSI, MESA, donor eggs, gestational surrogacy, IUI procedure, ovulation induction and reproductive surgery. Both Dr. Chetkowski and Dr. Herndon are board-certified in Reproductive Endocrinology and Infertility. The Alta Bates IVF Program offers the best of clinical care in a warm and supportive community-based setting. Many of our patients have complex infertility factors or have failed treatments elsewhere, so they often benefit from the individualized care, meticulous attention to detail and the depth of clinical experience unique to our program. Contact: Barbara McSorley, 510-649-0440, [email protected], www.ABivf.com.
About the Marin Fertility Center, Greenbrae, CA
Marin Fertility Center is one of Northern California's premiere fertility programs, offering personalized care using a number of novel treatment approaches, including IVM and Moderate IVF™. Marin Fertility Center uses new technology to reimagine the patient experience, reducing the amount of medication and office visits required and resulting in less prohibitive costs. The clinic is led by Dr. Peter Uzelac, a Board-Certified expert in Reproductive Endocrinology and Infertility. Contact: Jamie Vigil, 415-925-9404, [email protected]
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.